184 related articles for article (PubMed ID: 6825121)
1. Phase I trial of 10-deaza-aminopterin in patients with advanced cancer.
Currie VE; Warrell RP; Arlin Z; Tan C; Sirotnak FM; Greene G; Young CW
Cancer Treat Rep; 1983 Feb; 67(2):149-54. PubMed ID: 6825121
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate.
Krug LM; Ng KK; Kris MG; Miller VA; Tong W; Heelan RT; Leon L; Leung D; Kelly J; Grant SC; Sirotnak FM
Clin Cancer Res; 2000 Sep; 6(9):3493-8. PubMed ID: 10999734
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer.
Kris MG; Kinahan JJ; Gralla RJ; Fanucchi MP; Wertheim MS; O'Connell JP; Marks LD; Williams L; Farag F; Young CW
Cancer Res; 1988 Oct; 48(19):5573-9. PubMed ID: 3416310
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin.
Laurie SA; Pfister DG; Kris MG; Tong WP; Chronowski G; Pisters KM; Heelan RT; Sirotnak FM
Clin Cancer Res; 2001 Mar; 7(3):501-9. PubMed ID: 11297240
[TBL] [Abstract][Full Text] [Related]
5. Clinical and pharmacological evaluation of triazinate in humans.
Skeel RT; Cashmore AR; Sawicki WL; Bertino JR
Cancer Res; 1976 Jan; 36(1):48-54. PubMed ID: 1248009
[TBL] [Abstract][Full Text] [Related]
6. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
D'Andrea G; Fennelly D; Norton L; Baselga J; Gilewski T; Hudis C; Moynahan ME; Raptis G; Sklarin N; Surbone A; Theodoulou M; Templeton MA; Yao TJ; Seidman AD
Clin Cancer Res; 1999 Feb; 5(2):275-9. PubMed ID: 10037175
[TBL] [Abstract][Full Text] [Related]
8. Final results of a phase I and pharmacokinetic study of gamma-methylene-10-deazaaminopterin (MDAM) administered intravenously daily for five consecutive days in patients with solid tumors.
Johansen M; Zukowski T; Hoff PM; Newman RA; Ni D; Hutto T; Abbruzzeese J; Berghorn E; Hausheer F; Madden T
Cancer Chemother Pharmacol; 2004 May; 53(5):370-6. PubMed ID: 15060739
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of 10-deazaaminopterin for advanced hypernephroma.
Scher HI; Yagoda A; Ahmed T; Hollander P; Watson RC
Anticancer Res; 1984; 4(6):409-10. PubMed ID: 6517533
[TBL] [Abstract][Full Text] [Related]
10. High-dose edatrexate with oral leucovorin rescue: a phase I and clinical pharmacological study in adults with advanced cancer.
Pisters KM; Tyson LB; Tong W; Fleisher M; Miller VA; Grant SC; Pfister DG; Rigas JR; Densmore CL; Krol G; Heelan RT; Sirotnak FM; Bertino JR; Kris MG
Clin Cancer Res; 1996 Nov; 2(11):1819-24. PubMed ID: 9816135
[TBL] [Abstract][Full Text] [Related]
11. New folate analogs of the 10-deaza-aminopterin series: markedly increased antitumor activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumor xenografts in nude mice.
Schmid FA; Sirotnak FM; Otter GM; DeGraw JI
Cancer Treat Rep; 1985 May; 69(5):551-3. PubMed ID: 4005878
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of 10-Edam in patients with advanced colorectal carcinoma.
Kemeny N; Israel K; O'Hehir M
Am J Clin Oncol; 1990 Feb; 13(1):42-4. PubMed ID: 2305719
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of 10-deaza-aminopterin in advanced breast cancer.
Thongprasert S; Currie VE; Budman D
Cancer Treat Rep; 1987 Jan; 71(1):95-6. PubMed ID: 3791275
[No Abstract] [Full Text] [Related]
14. Neocarzinostatin: report of a phase II clinical trial.
McKelvey EM; Murphy W; Zander A; Bodey GP
Cancer Treat Rep; 1981; 65(7-8):699-701. PubMed ID: 6454486
[TBL] [Abstract][Full Text] [Related]
15. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T
Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of homoharringtonine administered as a 5-day continuous infusion.
Coonley CJ; Warrell RP; Young CW
Cancer Treat Rep; 1983; 67(7-8):693-6. PubMed ID: 6871884
[TBL] [Abstract][Full Text] [Related]
17. A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors.
Grem JL; Kos ME; Evande RE; Meza JL; Schwarz JK
Cancer; 2015 Nov; 121(21):3862-8. PubMed ID: 26242208
[TBL] [Abstract][Full Text] [Related]
18. Intracavitary therapy of murine ovarian cancer with cis-diamminedichloroplatinum(II) and 10-ethyl-10-deazaaminopterin incorporating systemic leucovorin protection.
Sirotnak FM; Schmid FA; DeGraw JI
Cancer Res; 1989 Jun; 49(11):2890-3. PubMed ID: 2785847
[TBL] [Abstract][Full Text] [Related]
19. Initial clinical study with pyrazofurin.
Ohnuma T; Holland JF
Cancer Treat Rep; 1977; 61(3):389-94. PubMed ID: 872139
[TBL] [Abstract][Full Text] [Related]
20. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.
Sosman JA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Weiss GR; Isaacs RE; Margolin KA; Fisher RI; Ernest ML; Mier J; Oleksowicz L; Eckhardt JR; Levitt D; Doroshow JH
Clin Cancer Res; 1997 Jan; 3(1):39-46. PubMed ID: 9815535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
